Oraya Therapeutics

Apr 18, 2013 | The Wall Street Journal

Oraya Therapeutics’ INTREPID Study Published in Ophthalmology, the Official Journal of the American Academy of Ophthalmology >> More

Apr 1, 2013 | New Retina MD

Radiation Therapy for Neovascular Age-related Macular Degeneration >> More

Mar 4, 2013 | Mail Online

The X-ray beam that could end painful jabs for ageing eyes >> More

Mar 1, 2013 | Ophthalmology Times

INTREPID identifies ‘best responders’: Fewer anti-VEGF injections among benefits of stereotactic radiotherapy for wet AMD >> More

Feb 27, 2013 | Insight Radio

Revolutionary Treatment for AMD Launched >> More

Feb 26, 2013 | Yahoo!7 News

Hope for eye disease sufferers >> More

Feb 25, 2013 | ITV

New hope for macular degeneration >> More

Feb 11, 2013 | SMT Online

OnCore Opens Medical Center-of-Excellence >> More

Dec 22, 2012 | Mail Online

Revolutionary X-ray treatment offers hope for diseased eyes >> More

Nov 28, 2012 | AZoRobtics

Non-Invasive Robotic Device Delivers Radiotherapy for Eye Disease >> More

Nov 20, 2012 | The Telegraph

Macular degeneration: new hope for elderly victims of disease that causes blindness. Nick Collins, Science Correspondent >> More

Oct 25, 2012 | Ocular Surgery News

Noninvasive radiotherapy reduces need for repeated anti-VEGF injections in AMD >> More

Oct 1, 2012 | Retina Today

Stereotatic Radiotherapy: Results of the INTREPID Study. Timothy L. Jackson, PhD, FRCOphth >> More

Back To Top

The INTREPID Trial of Stereotactic Radiosurgery for Choroidal Neovascularization
in AMD
- Peter K. Kaiser, M.D.
© 2013 All rights reserved to Oraya Therapeutics The IRay® Radiotherapy System is an investigational device and is not available for sale in the U.S.A. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.